Among the most advanced candidates is Verve Therapeutics’ VERVE-101, a CRISPR-based therapy targeting the PCSK9 gene, now in Phase 1 clinical trial for familial hypercholesterolemia. This evidence concerns the gene PCSK9 and familial hypercholesterolemia.